Granted Patent B2

US 8,802,104 · App. 13/667,361 · Granted Aug 12, 2014

Inventors: David T. Scadden (Weston, MA); Laura M. Calvi (Rochester, NY); Gregor Adams (South Pasadena, CA); Henry M. Kronenberg (Belmont, MA)

Assignee: The General Hospital Corporation

C12N5/0602A61K35/28C12Q1/6809A01K2227/105C12N5/0647C12N5/0675C12N2501/37C12N2502/1311C12N2502/1394C07K14/72G01N33/74A61K38/29C12N5/0623A01K2217/05A61K38/17

Abstract

Claims (10)

1. A method for preparing a population of cells for enhancing the growth or maintenance of stem cells selected from the group consisting of mesenchymal stem cells, epithelial stem cells and neural stem cells, the method comprising:

contacting a cell expressing a PTH/PTHrP receptor with an agent that activates the PTH/PTHrP receptor in an amount effective to support the growth or maintenance of mesenchymal stem cells, epithelial stem cells or neural stem cells.

2. The method of claim 1 , wherein the cell expressing a PTH/PTHrP receptor is present in the immediate vicinity of a mesenchymal stem cell, an epithelial stem cell or a neural stem cell.

3. The method of claim 1 , wherein the cell expressing a PTH/PTHrP receptor is chosen from a bone, breast, skin, epithelial, lung, urogenital and gastrointestinal cell.

4. The method of claim 1 , wherein said contacting the cell expressing a PTH/PTHrP receptor with an agent that activates the PTH/PTHrP receptor occurs in vitro or in vivo.

5. The method of claim 1 , wherein the agent that activates the PTH/PTHrP receptor is PTH, a PTH analogue, or a PTH/PTHrP receptor agonist.

6. The method of claim 1 , wherein the growth and maintenance of mesenchymal stem cells, epithelial stem cells or neural stem cells occurs in vitro or in vivo.

7. The method of claim 2 , wherein the cell expressing a PTH/PTHrP receptor is present in the immediate vicinity of a neural stem cell and is selected from the group consisting of a astrocyte, oligodendrocyte, glial cell, GABAergic neuron dopaminergic neuron and a cell of the cerebellum, telencephalon, diencephalons, mesencephalon, medulla, pons, thalamus, hippocampus, trigeminal ganglion or leptomeninges.

8. The method of claim 1 , wherein the agent that activates the PTH/PTHrP receptor is a PTH analogue, or a PTH/PTHrP receptor agonist.

9. The method of claim 8 , wherein the PTH is selected from the group consisting of PTH(1-84), PTH(1-31), PTH(1-34), PTH(1-36), PTH(1-37), PTH(1-38), PTH(1-41), PTH(28-48) and PTH(25-39).

Continuity (8)